162 related articles for article (PubMed ID: 25261237)
1. In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.
Balkin ER; Kenoyer A; Orozco JJ; Hernandez A; Shadman M; Fisher DR; Green DJ; Hylarides MD; Press OW; Wilbur DS; Pagel JM
Cancer Res; 2014 Oct; 74(20):5846-54. PubMed ID: 25261237
[TBL] [Abstract][Full Text] [Related]
2. Cerenkov luminescence imaging of medical isotopes.
Ruggiero A; Holland JP; Lewis JS; Grimm J
J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
[TBL] [Abstract][Full Text] [Related]
3. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
4. Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Lohrmann C; Zhang H; Thorek DL; Desai P; Zanzonico PB; O'Donoghue J; Irwin CP; Reiner T; Grimm J; Weber WA
J Nucl Med; 2015 May; 56(5):805-11. PubMed ID: 25840974
[TBL] [Abstract][Full Text] [Related]
5. Cerenkov luminescence imaging of αv β6 integrin expressing tumors using (90) Y-labeled peptides.
Satpati D; Hausner SH; Bauer N; Sutcliffe JL
J Labelled Comp Radiopharm; 2014 Jul; 57(9):558-65. PubMed ID: 25042833
[TBL] [Abstract][Full Text] [Related]
6. Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.
Maier FC; Schmitt J; Maurer A; Ehrlichmann W; Reischl G; Nikolaou K; Handgretinger R; Pichler BJ; Thaiss WM
Oncotarget; 2016 Oct; 7(41):67403-67411. PubMed ID: 27602580
[TBL] [Abstract][Full Text] [Related]
7. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
8. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
[TBL] [Abstract][Full Text] [Related]
9. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
10. Cerenkov luminescence endoscopy: improved molecular sensitivity with β--emitting radiotracers.
Carpenter CM; Ma X; Liu H; Sun C; Pratx G; Wang J; Gambhir SS; Xing L; Cheng Z
J Nucl Med; 2014 Nov; 55(11):1905-9. PubMed ID: 25300598
[TBL] [Abstract][Full Text] [Related]
11. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.
Chakravarty R; Chakraborty S; Sarma HD; Nair KV; Rajeswari A; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):354-63. PubMed ID: 27264196
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements.
Habte F; Natarajan A; Paik DS; Gambhir SS
Mol Imaging; 2018; 17():1536012118788637. PubMed ID: 30043654
[TBL] [Abstract][Full Text] [Related]
13. Hybrid Light Imaging Using Cerenkov Luminescence and Liquid Scintillation for Preclinical Optical Imaging In Vivo.
Shimamoto M; Gotoh K; Hasegawa K; Kojima A
Mol Imaging Biol; 2016 Aug; 18(4):500-9. PubMed ID: 26819217
[TBL] [Abstract][Full Text] [Related]
14. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
15. Cerenkov Luminescence Imaging (CLI) for cancer therapy monitoring.
Xu Y; Liu H; Chang E; Jiang H; Cheng Z
J Vis Exp; 2012 Nov; (69):e4341. PubMed ID: 23183774
[TBL] [Abstract][Full Text] [Related]
16. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
[TBL] [Abstract][Full Text] [Related]
17. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
19. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
[TBL] [Abstract][Full Text] [Related]
20. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and
Orozco JJ; Kenoyer AL; Lin Y; O'Steen S; Guel R; Nartea ME; Hernandez AH; Hylarides MD; Fisher DR; Balkin ER; Hamlin DK; Wilbur DS; Orcutt KD; Wittrup KD; Green DJ; Gopal AK; Till BG; Sandmaier B; Press OW; Pagel JM
Mol Cancer Ther; 2020 Dec; 19(12):2575-2584. PubMed ID: 33082277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
